Posted by Michael Wonder on 24 Jun 2021
Santen receives FDA approval for Verkazia (cyclosporin 0.1% ophthalmic emulsion) for the treatment of vernal keratoconjunctivitis in children and adults
24 June 2021 - Santen today announced that the U.S. FDA has approved Verkazia (cyclosporin 0.1% ophthalmic emulsion eye drops) for the treatment of vernal keratoconjunctivitis in children and adults.
The safety and efficacy of Verkazia for the treatment of vernal keratoconjunctivitis was evaluated in two randomised, multi-center, double-masked, vehicle-controlled, clinical trials (VEKTIS and NOVATIVE).
